Last reviewed · How we verify

Hifenac — Competitive Intelligence Brief

Hifenac (ACECLOFENAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aceclofenac. Area: Immunology.

marketed aceclofenac Transthyretin Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Hifenac (ACECLOFENAC).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hifenac TARGET ACECLOFENAC marketed aceclofenac Transthyretin
Amvuttra VUTRISIRAN Alnylam Pharmaceuticals marketed Small Interfering RNA transthyretin (TTR) mRNA 2022-01-01
Vyndaqel Tafamidis Foldrx Pharms marketed tafamidis Transthyretin 2019-01-01
Vyndaqel tafamidis Foldrx Pharms marketed tafamidis Transthyretin 2019-01-01
Vyndaqel tafamidis-test Foldrx Pharms marketed tafamidis Transthyretin 2019-01-01
Vyndaqel Tafamidis Meglumine Foldrx Pharms marketed Transthyretin stabilizer Transthyretin (TTR) 2019-01-01
Egaten TRICLABENDAZOLE Novartis marketed Anthelmintic [EPC] Transthyretin 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (aceclofenac class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hifenac — Competitive Intelligence Brief. https://druglandscape.com/ci/aceclofenac. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: